- Home
- NCMI vs PALI Comparison
NCMI vs PALI Comparison
Compare NCMI & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCMI | PALI |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 359.7M |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NCMI | PALI |
|---|---|---|
| Price | $3.49 | $1.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.63 | ★ $11.29 |
| AVG Volume (30 Days) | 387.2K | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | 52.17 | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | $11.20 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $2.80 | $0.55 |
| 52 Week High | $5.14 | $2.86 |
Technical Indicators
Market Signals| Indicator | NCMI | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 54.58 |
| Support Level | $3.35 | $1.57 |
| Resistance Level | $3.70 | $2.12 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 31.40 | 72.62 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.